Summary & Overview
HCPCS C9092: Triamcinolone Acetonide Suprachoroidal Injection, 1 mg
HCPCS Level II code C9092 denotes the suprachoroidal injection of triamcinolone acetonide (Xipere), 1 mg, a targeted ophthalmic therapy for posterior segment eye disease. As a novel route of administration, this code captures a specialized in-office or outpatient procedure with potential implications for specialty drug management, pharmacy benefit integration, and prior authorization workflows nationwide. The code matters because it differentiates suprachoroidal delivery from intravitreal or systemic corticosteroid therapies, affecting coding, reimbursement pathways, and utilization tracking.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical service, typical sites of care, and the administrative context for billing this HCPCS Level II code. The publication outlines common modifiers associated with procedural billing, discusses payer coverage considerations and authorization touchpoints, and highlights related clinical and billing contexts relevant to ophthalmology practices and ASC operations.
This summary equips billing leaders, compliance officers, and ophthalmology clinicians with the essential framing to understand where C9092 fits within procedure coding, payer interactions, and outpatient service delivery. Data not available in the input will be identified in subsequent sections.
Billing Code Overview
HCPCS Level II code C9092 represents injection of triamcinolone acetonide delivered via the suprachoroidal space (Xipere), 1 mg. This service involves an intraocular pharmaceutical injection specifically formulated and administered suprachoroidally for posterior segment ocular conditions.
Service Type: Therapeutic ophthalmic injection
Typical Site of Service: Outpatient ophthalmology clinic, ambulatory surgery center, or hospital outpatient department, where intraocular injections and specialty ophthalmic procedures are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic macular edema secondary to uveitic or retinal vein occlusion etiologies who presents to an ambulatory ophthalmology procedure suite for a suprachoroidal injection of triamcinolone acetonide (C9092, Xipere). The patient has been evaluated in clinic with best-corrected visual acuity, intraocular pressure measurement, slit-lamp exam, dilated fundus exam, and optical coherence tomography (OCT) confirming intraretinal or subretinal fluid and an indication for a targeted suprachoroidal corticosteroid delivery.
The clinical workflow: pre-procedure verification and informed consent are completed; topical and/or subconjunctival anesthesia is administered; sterile field and eyelid speculum are applied; the suprachoroidal microinjector delivers 1 mg of triamcinolone acetonide into the suprachoroidal space under direct visualization or using anatomical landmarks. Post-injection vital signs and ocular pressure are checked, post-procedure instructions given, and follow-up OCT and clinic visit are scheduled to monitor response and intraocular pressure. Documentation includes indication, laterality, informed consent, drug name and dose (triamcinolone acetonide 1 mg suprachoroidal), technique, any immediate complications, and follow-up plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|